Yumanity Therapeutics Inc (YMTX)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Richard Peters
Employees:
48
40 Guest Street, Suite 4410, Boston MA 02135.
617-409-5300.

We are a clinical stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis, or CF, through theratyping, or the process of matching modulators to individual response to treatment regardless of CFTR mutations. CF is a disease caused by defects in the function or abundance of cystic fibrosis transmembrane conductance regulator, or CFTR protein. Although, CF is defined as a monogenic recessive genetic disorder caused by mutations in the CFTR gene, there is a broad range of disease activity for different organ systems in CF, including lung disease, meconium ileus, diabetes, and liver disease, even for CF patients who are homozygous for the most common mutation, F508del mutation. In summary, CF genotype does not always match CF phenotype.

Data derived from most recent annual or quarterly report
Market Cap 12.021 Million Shares Outstanding10.83 Million Avg 30-day Volume 48.214 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-2.96
Price to Revenue3.9851 Debt to Equity0.5602 EBITDA-38.198 Million
Price to Book Value1.3643 Operating Margin-481.66339999999997 Enterprise Value8.717 Million
Current Ratio1.885 EPS Growth0.822 Quick Ratio1.831
1 Yr BETA 1.8402 52-week High/Low 16.89 / 0.95 Profit Margin-491.0865
Operating Cash Flow Growth-172.6893 Altman Z-Score-5.2049 Free Cash Flow to Firm -40.214 Million
Earnings Report2022-08-11

Are you looking for this stock instead?

View SEC Filings from YMTX instead.

View recent insider trading info

Yumanity Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding YMTX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding YMTX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

10.7 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PETERS RICHARD PRESIDENT AND CEO

  • Officer
  • Director
 115,708 2022-03-28 3

MOHSEN PAULASH CHIEF BUSINESS OFFICER

  • Officer
 59,135 2022-02-03 2

SMITH DEVIN WHITTEMORE SVP AND GENERAL COUNSEL

  • Officer
 20,000 2021-12-01 3

VERMA AJAY EVP, HEAD OF R&D

  • Officer
 30,200 2021-12-01 2

EPSTEIN MARIE PRINCIPAL ACCOUNTING OFFICER

  • Officer
 12,665 2021-12-01 1

WYZGA MICHAEL D SEE REMARKS

  • Officer
 20,000 2021-12-01 3

PICKETT CECIL B

  • Director
 14,800 2021-06-02 1

ARKOWITZ DAVID

  • Director
 14,800 2021-06-02 1

DRAPKIN KIMBERLEE C

  • Director
 14,800 2021-06-02 1

ALLEN PATRICIA L

  • Director
 14,800 2021-06-02 1

HEYMAN RICHARD A.

  • Director
 14,800 2021-06-02 1

KELLY JEFFERY W.

  • Director
 14,800 2021-06-02 1

ZYDOWSKY LYNNE

  • Director
 14,800 2021-06-02 1

COLES N ANTHONY EXECUTIVE CHAIR

  • Officer
  • Director
 78,650 2021-04-01 0

ROBERTSON BRIGITTE CHIEF MEDICAL OFFICER

  • Officer
 0 2021-02-01 0

SUSAN L. LINDQUIST FAMILY TRUST

SUSAN L. LINDQUIST EXEMPT MARITAL TRUST

SUSAN L. LINDQUIST MASSACHUSETTS NON-EXEMPT MARITAL TRUST

SUSAN L. LINDQUIST MASSACHUSETTS ONLY MARITAL TRUST

  • 10% Owner
 1,184,561 2020-12-22 0

BERGER FRANKLIN M

  • Director
 0 2020-06-29 0

DULAC EMMANUEL

  • Director
 0 2020-06-29 0

CHOWDHURY BADRUL A.

  • Director
 0 2020-06-29 0

ALFIERI MICHAEL INTERIM HEAD OF FINANCE

  • Officer
 0 2020-05-12 0

CHHABRA MEENU PRESIDENT AND CEO

  • Officer
  • Director
 0 2020-03-02 0

MUNOZ BENITO CHIEF SCIENTIFIC OFFICER

  • Officer
 0 2020-03-02 0

LARSON ERIC D SEE REMARKS

  • Officer
 0 2020-03-02 0

GILMARTIN GEOFFREY S. CHIEF MEDICAL OFFICER

  • Officer
 0 2020-03-02 0

ZECEVIC MARIJA CHIEF COMMERCIAL OFFICER

  • Officer
 0 2020-03-02 0

WILSON SHEILA CHIEF OPERATING OFFICER

  • Officer
 0 2020-03-02 0

NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

NEA PARTNERS 12, LIMITED PARTNERSHIP

NEA 12 GP, LLC

BARRIS PETER J

BASKETT FOREST

KERINS PATRICK J

SANDELL SCOTT D

  • 10% Owner
 No longer subject to file 2019-11-26 0

LEE PO SHUN SEE REMARKS

  • Officer
 0 2019-03-01 0

ZIMMERMAN SANDRA M. SEE REMARKS

  • Officer
 0 2018-08-06 0

BARRETT M JAMES

  • Director
  • 10% Owner
 0 2018-06-15 0

RABINOWITZ ERIC

  • Director
 0 2018-06-15 0

BOUDREAU HELEN M CHIEF FINANCIAL OFFICER

  • Officer
 0 2018-03-01 0

CORMORANT ASSET MANAGEMENT, LLC

CHEN BIHUA

CORMORANT GLOBAL HEALTHCARE GP, LLC

CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

  • Director
  • 10% Owner
 No longer subject to file 2017-12-14 0

HAGEN BRETT R SEE REMARKS

  • Officer
 0 2017-04-03 0

FMR LLC

  • SEE REMARK 1
 No longer subject to file 2017-03-13 0

NEW ENTERPRISE ASSOCIATES 12, LIMITED PARTNERSHIP

NEA PARTNERS 12, LIMITED PARTNERSHIP

NEA 12 GP, LLC

BARRIS PETER J

BASKETT FOREST

KERINS PATRICK J

KOLLURI KRISHNA KITTU

SANDELL SCOTT D

  • 10% Owner
 3,554,610 2016-09-14 0

DETORE JAMES M. SEE REMARKS

  • Officer
 0 2016-08-04 0

MIRABELLI CHRISTOPHER

HEALTHCARE VENTURES VIII, L.P.

CAVANAUGH JAMES H

HEALTHCARE PARTNERS VIII, LLC

HEALTHCARE PARTNERS VIII, L.P.

LAWLOR AUGUSTINE

LITTLECHILD JOHN W

WERNER HAROLD R

  • Director
  • 10% Owner
 2,164,095 2016-02-17 0

NOVARTIS BIOVENTURES LTD

NOVARTIS AG

  • 10% Owner
 No longer subject to file 2016-02-17 0

PERRIGO CO PLC

PERRIGO HOLDINGS LTD.

ELAN PHARMA INTERNATIONAL LTD.

PERRIGO CORP LTD.

PERRIGO SCIENCE ONE LTD.

  • 10% Owner
 2,908,067 2016-02-10 0

WALSH CHRISTOPHER T PHD

  • Director
 0 2016-02-10 0

THIBAULT LANCE E SEE REMARKS

  • Officer
 0 2016-02-10 0

MIRABELLI CHRISTOPHER

  • Director
  • 10% Owner
 0 2016-02-10 0

ELAN SCIENCE ONE LTD

  • 10% Owner
 0 2016-02-10 0

MIRZAC ROMEO PRINCIPAL ACCOUNTING OFFICER

  • Officer
 0 2016-02-10 0

SMART JANET L SEE REMARKS

  • Officer
 0 2016-02-10 0

WALSHE CONOR M

  • Director
 0 2016-02-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

PETERS RICHARD - Director - Officer PRESIDENT AND CEO

2022-03-30 16:05:14 -0400 2022-03-28 S 10,715 $1.85 d 115,708 direct yes 2.0 6.0 -20.0 6.0 6 -32.0 30

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 22:15:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 21:45:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 21:15:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 20:45:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 20:15:05 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 19:45:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 19:15:04 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 18:45:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 18:15:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 17:45:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 17:15:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 16:45:04 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 16:15:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 15:45:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 15:15:03 UTC -0.4186 1.2386 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 14:45:03 UTC -0.426 1.246 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 14:15:04 UTC -0.426 1.246 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 13:45:03 UTC -0.426 1.246 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 13:15:03 UTC -0.426 1.246 150000
YUMANITY THERAPEUTICS INC YMTX 2022-05-20 12:45:03 UTC -0.426 1.246 150000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments